Monopar Therapeutics Inc.
- MNPR
- NASDAQ
- Biotechnology
- Oncology Drug Development
- Monoclonal Antibodies
$71.47
Today +3.18%Quote Oct 19, 2026, 08:00 PM UTC
−25.91%over the last month
Max drawdown −28.3%From 1-month high −26.0%3 months −37.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Monopar Therapeutics
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
22
Founded
2014
Market value
$479.7M
Quote Oct 19
Floor
$65.52
8.3% below price
Resistance
$72.56
1.5% above price
Price vs analyst targets
14 analysts
Lowest target
$105.00Highest target
$145.00
$105.00Highest target
$145.00
- Price $71.47
- Average target $126.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 76% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about MNPRPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free